Drug Delivery Composition Comprising Polymerlipid Hybrid Microparticles

Abstract/Technology Overview

Lipid systems have been widely used in drug delivery applications, however issues arise due to instability, insufficient drug loading and burst release of encapsulated drug molecules. Alternatively, established polymeric nanoparticles can control drug release and sustain circulation whilst providing higher stability in biological fluids, however, the biocompatibility is not as high as lipid systems.

We have developed novel PLGAlipid hybrid (PLH) microparticles that combine the stabilising and controlled delivery characteristics of PLGA nanoparticles with the solubilizing effect of lipid droplets. This novel drug delivery formulation can be used in a wide range of therapeutic applications, including combination therapy with tuneable dispersion and controlled drug release.

Technology Features, Specifications and Advantages

The PLH microparticles increase the solubility of poorly water soluble drugs by dissolving the drug in the hydrophobic PLGA nanoparticles and lipid droplets. This drug delivery technology has the potential to:

  • Mimic the pharmaceutical food affect, thereby removing the need to take medication with a meal and increasing the therapeutic value of a range of drugs
  • For a mono-therapy, deliver the drug through 2 different mechanisms and hence increase uptake, change the absorption dynamics and improve pharmacokinetics 
  • For a combination therapy, deliver 2 separate drugs in a single formulation

The PLH microparticles have the potential to be used by the pharmaceutical industry as a drug carrier for the delivery of a wide range of hydrophobic drugs. Routes for administration include: oral, implantable, inhalation.

Potential Applications

This novel hybrid drug delivery formulation can be used in a wide range of therapeutic applications. The technology would be most valuable for the following companies:

  • Pharmaceutical companies
  •  Companies associated with the formulation and delivery of drugs

We are seeking commercial partners for drug delivery and formulation co-development and licensing opportunities.

Customer Benefit

  • Controlled drug encapsulation, release and delivery
  • Expanded pharmaceutical applications
  • Increased solubility of drugs
  •  Drug carrier for a wide range of hydrophobic drugs

Contact Person

Viraj Perera


UniSA Ventures Pty Ltd

Technology Category
  • Pharmaceuticals & Therapeutics
Technology Status
  • Available for Licensing
Technology Readiness Level
  • TRL 2

drug delivery, drug delivery formulation, polymer-liquid hybrid, PLH, PLH microparticles, hyrdophobic drugs